Evaluation of the Compatibility of Moxifloxacin with Selected Excipients Used in the Formulation of Nanopharmaceuticals
Drug excipients are chemical substances that can interact with each other and with APIs, thus affecting characteristics of the final dosage form. Selection of excipients for the preparation of nanopharmaceuticals is very critical because there are more chances of physical and chemical interactions. The current study was carried out to investigate the possibility of any chemical or physical interaction between moxifloxacin hydrochloride and selected excipients (polymers and surfactants) used in the formulation of polymeric nanoparticles. Samples were prepared using the binary mixture approach and then stored under stress conditions (40 ± 2°C and 75 ± 5% RH) for 90 days. The compatibility studies were carried out by visual observations, HPLC-UV, XRD and FTIR analysis. No visual changes were observed in any of the samples, drug content of the samples was within the range of 98 – 100.37%. FTIR spectra remained unaffected, and all the characteristic XRD peaks were present which indicated that the drug was compatible with the excipients used. The results of this investigation confirm that moxifloxacin hydrochloride is compatible with the selected excipients, and the polymeric drug nanoparticles can be formulated without any stability issues..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Pharmaceutical chemistry journal - 55(2022), 11 vom: Feb., Seite 1184-1189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Fahim Ullah [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Excipients |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s11094-022-02556-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078159050 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078159050 | ||
| 003 | DE-627 | ||
| 005 | 20230515192551.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11094-022-02556-8 |2 doi | |
| 035 | |a (DE-627)OLC2078159050 | ||
| 035 | |a (DE-He213)s11094-022-02556-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Khan, Fahim Ullah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the Compatibility of Moxifloxacin with Selected Excipients Used in the Formulation of Nanopharmaceuticals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Drug excipients are chemical substances that can interact with each other and with APIs, thus affecting characteristics of the final dosage form. Selection of excipients for the preparation of nanopharmaceuticals is very critical because there are more chances of physical and chemical interactions. The current study was carried out to investigate the possibility of any chemical or physical interaction between moxifloxacin hydrochloride and selected excipients (polymers and surfactants) used in the formulation of polymeric nanoparticles. Samples were prepared using the binary mixture approach and then stored under stress conditions (40 ± 2°C and 75 ± 5% RH) for 90 days. The compatibility studies were carried out by visual observations, HPLC-UV, XRD and FTIR analysis. No visual changes were observed in any of the samples, drug content of the samples was within the range of 98 – 100.37%. FTIR spectra remained unaffected, and all the characteristic XRD peaks were present which indicated that the drug was compatible with the excipients used. The results of this investigation confirm that moxifloxacin hydrochloride is compatible with the selected excipients, and the polymeric drug nanoparticles can be formulated without any stability issues. | ||
| 650 | 4 | |a moxifloxacin hydrochloride | |
| 650 | 4 | |a incompatibility | |
| 650 | 4 | |a excipients | |
| 650 | 4 | |a x-ray diffraction | |
| 650 | 4 | |a HPLC-UV | |
| 650 | 4 | |a FTIR | |
| 700 | 1 | |a Nasir, Fazli |4 aut | |
| 700 | 1 | |a Hassan, Muhammad |4 aut | |
| 700 | 1 | |a Khan, Amjad |4 aut | |
| 700 | 1 | |a Ullah, Aman |4 aut | |
| 700 | 1 | |a Rabbi, Fazle |4 aut | |
| 700 | 1 | |a Shahbaz, Naila |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical chemistry journal |d Springer US, 1967 |g 55(2022), 11 vom: Feb., Seite 1184-1189 |w (DE-627)130010669 |w (DE-600)418538-9 |w (DE-576)015555631 |x 0091-150X |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2022 |g number:11 |g month:02 |g pages:1184-1189 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11094-022-02556-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2022 |e 11 |c 02 |h 1184-1189 | ||